Drug Profile
Research programme: mTOR protein inhibitors - Array Biopharma
Alternative Names: AR-mTOR-1; AR-mTOR-26Latest Information Update: 02 Aug 2019
Price :
$50
*
At a glance
- Originator Array BioPharma
- Class
- Mechanism of Action MTORC1 protein inhibitors; MTORC2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 30 Jul 2019 Array Biopharma has been acquired by Pfizer
- 12 Aug 2011 No development reported - Preclinical for Cancer in USA (unspecified route)